Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model.
Metastatic prostate cancer continues to be the second leading cause of cancer death in American men with an estimated 28,660 deaths in 2008. Recently, monocyte chemoattractant protein-1 (MCP-1, CCL2) has been identified as an important factor in the regulation of prostate metastasis. CCL2, shown to attract macrophages to the tumor site, has a direct promotional effect on tumor cell proliferation, migration, and survival. Previous studies have shown that anti-CCL2 antibodies given in combination with docetaxel were able to induce tumor regression in a pre-clinical prostate cancer model. A limitation for evaluating new treatments for metastatic prostate cancer to bone is the inability of imaging to objectively assess response to treatment. Diffusion-weighted MRI (DW-MRI) assesses response to anticancer therapies by quantifying the random (i.e., Brownian) motion of water molecules within the tumor mass, thus identifying cells undergoing apoptosis. We sought to measure the treatment response of prostate cancer in an osseous site to docetaxel, an anti-CCL2 agent, and combination treatments using DW-MRI. Measurements of tumor apparent diffusion coefficient (ADC) values were accomplished over time during a 14-day treatment period and compared to response as measured by bioluminescence imaging and survival studies. The diffusion data provided early predictive evidence of the most effective therapy, with survival data results correlating with the DW-MRI findings. DW-MRI is under active investigation in the pre-clinical and clinical settings to provide a sensitive and quantifiable means for early assessment of cancer treatment outcome.
Rozel
Stefan
S
Department of Biomedical Engineering, Biomedical NMR, Eindhoven, University of Technology, Eindhoven, The Netherlands.
Galbán
Craig J
CJ
Nicolay
Klaas
K
Lee
Kuei C
KC
Sud
Sudha
S
Neeley
Chris
C
Snyder
Linda A
LA
Chenevert
Thomas L
TL
Rehemtulla
Alnawaz
A
Ross
Brian D
BD
Pienta
Kenneth J
KJ
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D018932:Chemokine CCL2 / Q000037:antagonists & inhibitors* / Q000276:immunology; D038524:Diffusion Magnetic Resonance Imaging; D000077143:Docetaxel; D004357:Drug Synergism; D006801:Humans; D008297:Male; D051379:Mice; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology; D043823:Taxoids / Q000627:therapeutic use*; D023041:Xenograft Model Antitumor Assays
D000906:Antibodies; D000970:Antineoplastic Agents; D018932:Chemokine CCL2; D043823:Taxoids; D000077143:Docetaxel